CLINICAL TRIALS PROFILE FOR ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
✉ Email this page to a colleague
All Clinical Trials for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00078247 ↗ | Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis | Completed | Makerere University | Phase 3 | 2004-10-01 | This study is designed to determine whether 6 months of anti-HIV drugs given along with tuberculosis treatment will delay the onset of AIDS in HIV infected African patients. |
| NCT00078247 ↗ | Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2004-10-01 | This study is designed to determine whether 6 months of anti-HIV drugs given along with tuberculosis treatment will delay the onset of AIDS in HIV infected African patients. |
| NCT00084149 ↗ | Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 2004-02-01 | Cyclosporine A (CsA) is a common long-term treatment used to inhibit the immune response in transplant patients who receive donor organs. CsA may also help people with HIV. The purpose of this study is to determine the safety of and immune response to CsA when given with abacavir sulfate (ABC), lamivudine (3TC), and zidovudine (AZT), (ABC/3TC/AZT) and lopinavir/ritonavir (LPV/r) to HIV infected adults in the early stages of infection. Study hypothesis: The combination of CsA and LPV/r given to acutely infected individuals will result in lower levels of proviral DNA and latent infectious virus at 48 weeks compared to acute infected individuals treated with LPV/r alone. |
| NCT00102206 ↗ | A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 2 | 1969-12-31 | HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment. |
| NCT00102206 ↗ | A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 | 1969-12-31 | HIV infected children and adolescents who have taken many anti-HIV drugs may have limited treatment options and are at high risk for progressing to AIDS. The purpose of this study is to determine whether an anti-HIV treatment regimen of 2 protease inhibitors (PIs) and 2 nucleoside reverse transcriptase inhibitors (NRTIs) is more effective than a regimen of 4 NRTIs in treatment-experienced children and adolescents who have failed previous anti-HIV treatment. |
| NCT00102960 ↗ | Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 3 | 2005-07-01 | The purpose of this study is to compare the effects of anti-HIV drug courses of different lengths in infants who became HIV infected at birth. |
| NCT00270296 ↗ | Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV | Completed | Harvard School of Public Health | Phase 2 | 2006-06-01 | Anti-HIV drug regimens have dramatically improved the rates of prevention of mother-to-child transmission (MTCT) of HIV in developed countries. However, little is known of the effectiveness of such regimens in developing countries, such as Botswana. This study will determine whether Trizivir (TZV), a single pill containing abacavir sulfate, lamivudine, and zidovudine (ABC/3TC/ZDV), or lopinavir/ritonavir (LPV/r) and lamivudine/zidovudine (3TC/ZDV) is more effective in reducing HIV-1 viral load and preventing MTCT among HIV infected pregnant women in Botswana. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
Condition Name
Clinical Trial Locations for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
Trials by Country
Clinical Trial Progress for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
Clinical Trial Phase
Clinical Trial Sponsors for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE
Sponsor Name
| Sponsor Name for ABACAVIR SULFATE, LAMIVUDINE AND ZIDOVUDINE | |
| Sponsor | Trials |
| National Institute of Allergy and Infectious Diseases (NIAID) | 5 |
| Harvard School of Public Health | 1 |
| Harvard School of Public Health (HSPH) | 1 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
